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a b s t r a c t
Chronic myelogenous leukemia (CML) is a cancer of the white blood cells that results from increased and
uncontrolled growth of myeloid cells in the bone marrow and the accumulation of these cells in the blood.
The most common form of treatment for CML is imatinib, a tyrosine kinase inhibitor. Although imatinib is
an effective treatment for CML and most patients treated with imatinib do attain some form of remission,
imatinib does not completely eradicate all leukemia cells, and if treatment is stopped, all patients eventually
relapse (Cortes, 2005). In Kim (2008), the authors developed a mathematical model for the dynamics of CML
under imatinib treatment that incorporates the anti-leukemia immune response, and in Paquin (2011), the
authors used this mathematical model to study strategic treatment interruptions as a potential therapeutic
strategy for CML patients. Although the authors presented the results of several numerical simulations in
Paquin (2011), the studies in that work did not include the possibility of imatinib-resistant mutations or an
initial population of imatinib-resistant leukemia cells. As resistance is a signiﬁcant consideration in any drug
treatment, it is important to study the eﬃcacy of the strategic treatment interruption plan in the presence
of imatinib resistance. In this work, we modify the delay differential equations model of Kim (2008), Paquin
(2011) to include the possibility of imatinib resistance, and we analyze strategic treatment interruptions as
a potential therapeutic tool in the case of patients with imatinib-resistance leukemia cells.

1. Introduction
Chronic myelogenous leukemia (CML) is a cancer of the blood
cells and bone marrow that causes uncontrolled growth of white
blood cells. In normal circumstances, the bone marrow makes immature blood stem cells that progress to become mature blood cells.
In patients with CML, too many stem cells become white blood
cells (called granulocytes, or leukemia cells), due to increased and
unregulated growth of myeloid cells in the bone marrow. These
cells then accumulate in the blood and bone marrow, and prevent development of healthy white blood cells, red blood cells, and
platelets [16].
Drug therapy programs for CML work by targeting the blood cells
that contain the abnormal gene responsible for the overabundance
of diseased blood cells. In particular, drugs for CML work by targeting the protein produced by this gene, tyrosine kinase. The standard
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treatment for CML is the tyrosine kinase inhibitor imatinib mesylate (marketed as Gleevec or Glivec) [1]. Other targeted drugs for
CML treatment include dasatinib and nilotinib. Imatinib does effectively treat CML, and most patients are able to attain some form of
remission with continuous, prolonged imatinib treatment. However,
imatinib does not completely eradicate all leukemia cells, and if the
treatment is stopped, patients eventually relapse [4,11,15,17]. Additionally, acquired resistance to imatinib treatment poses a signiﬁcant
problem for CML treatment programs [13,18].
In this work and in other landmark works on imatinib treatment
of CML [11,13–15,17], three standard types of remission are considered: hematologic, cytogenetic, and molecular. Each type of remission corresponds to a 2-log, or 100-fold, decrease compared to the
previous level. According to Lowenberg [9], each patient typically has
approximately 1012 leukemia cells prior to imatinib treatment. Thus,
hematologic remission corresponds to 1010 cells, cytogenetic remission corresponds to 108 cells, and molecular remission corresponds to
106 cells. Assuming that the average person has approximately 6 L of
blood, these remission levels correspond to the concentration levels
given in Table 1. With imatinib treatment, nearly all patients achieve

Table 1
Leukemia cell concentrations (in k/μL) corresponding to hematologic,
cytogenetic, and molecular remission levels.
Remission level

Hematologic

Cytogenetic

Molecular

Concentration (k/μL)

1.67

1.67 × 10−2

1.67 × 10−4

hematologic remission, and approximately 75% of patients achieve
cytogenetic remission [4,8,13].
Several mathematical models have been developed, simulated,
and analyzed to study the the pathogenesis, effects, and dynamics of
imatinib treatment of CML , including [6,7,11,14,17]. A review of several mathematical models of CML and the clinical insights provided
by the models is contained in [13]. In all of the models referenced
above, the authors conclude that imatinib does not completely eliminate the leukemia cell population, and propose that imatinib therapy
should be combined with an additional form of treatment. In [14],
the authors use a stochastic process model to simulate a competition
of normal and malignant stem cells for a common resource. In [11],
Michor et al. constructed a system of ordinary differential equations
to model the dynamics of CML with imatinib treatment. Their model
describes the progression of leukemia cells through four different life
stages, and stipulates that the progression of leukemia cells from one
stage to another is slowed with imatinib treatment. Kim et al. modiﬁed this ODE model in [6] to construct a system of delay differential
equations that includes not only the progression of leukemia cells
through life stages, but also interactions of leukemia cells with antileukemia T-cells. Their work indicates that the strength of a given
patient’s immune response may be an important factor in determining what type of remission the patient achieves, and how long the
patient remains in remission, while undergoing continuous imatinib
treatment.
In [12], Paquin et al. used the delay differential equations model
presented in [6] to study the effectiveness of strategic treatment interruptions as a potential clinical approach to enhancing the effects of
imatinib treatment for CML. The authors demonstrated that treatment
programs that involve strategic treatment interruptions in which imatinib treatment is temporarily stopped in order to leverage the antileukemia immune response may prevent leukemia from relapsing and
may prevent remission for signiﬁcantly longer than continuous imatinib treatment, and, in many cases, strategic treatment interruptions
may completely eliminate leukemic cells from the body. They also
used a series of numerical simulations to determine an optimal time
during which imatinib treatment should be temporarily stopped in
order to leverage the patient’s own anti-leukemia immune response.
However, in [12], the authors did not consider the possibility of imatinib resistance. In particular, it was assumed that it is not possible
for patients to develop imatinib-resistant leukemia cells, and that
patients do not initially have any imatinib-resistant leukemia cells
prior to starting treatment. As acquired and innate drug resistance
are important considerations in any drug therapy program, the natural next step following the work in [12] is to study the possible
eﬃcacy of strategic treatment interruptions when the patient may
develop imatinib resistance during treatment.
This paper is organized in the following way. We begin in Section 2
by modifying the delay differential equations model to include the
possibility of both pre-treatment imatinib-resistant cancer cells and
acquired imatinib resistance. We then derive estimates of the model
parameters using experimental data from [3]. We use the universal
model parameter values (i.e. the parameter values that are the same
for all patients) from [6], and we focus on using the data from [3]
to derive new values of patient-dependent parameters in the case of
imatinib resistance. In Section 3, we present and analyze the results of
several strategic treatment interruption simulations in the presence
of imatinib resistance, and we conclude that the success of strategic treatment interruptions in this case is largely dependent on the

strength of the patient’s immune response. In Section 4, we study the
sensitivity of the results to the universal and patient-speciﬁc parameters used in the model. Concluding remarks are in Section 5.

2. A mathematical model for imatinib treatment of CML with
imatinib resistance
In 2005, Michor et al. [11] constructed a differential equations
model of CML based on the architecture of the hematopoietic system.
In particular, this model describes the development of leukemia cells
through four subsequent life stages. The different concentrations of
cell populations (in k/μL, i.e. thousands of cells per microliter) at time
t are denoted as follows: y0 (t), leukemia stem cells; y1 (t), progenitor
cells; y2 (t), differentiated cells; and y3 (t), terminally differentiated
cells. Leukemia cells progress through these different life stages in the
following way. Stem cells regenerate themselves at rate ry . Stem cells
become progenitor cells at rate ay and die at rate r0 . Progenitor cells
become differentiated cells at rate by and die at rate d1 . Differentiated
cells become terminal cells at rate cy and die at rate d2 . Terminal cells
die at rate d3 . With imatinib treatment, ay and by are reduced by a
factor of 100 and 750, respectively, thus resulting in a decrease in the
overall leukemia concentration.
A second set z0 , z1 , z2 , z3 (imatinib-resistant stem, progenitor, differentiated, and terminally differentiated) of leukemia cells was included in this model to account for the possibility of resistance to
imatinib. It was assumed that only stem cells can acquire imatinib
resistance, and that mutations occur at a rate of u mutations per
division.
The system of ODEs that describes the mathematical model of
Michor et al. [11] is given below.

dy0
= (ry (1 − u) − d0 )y0 ,
dt

dz0
= (rz − d0 )z0 + ry uy0 ,
dt

dy1
= a y y0 − d 1 y1 ,
dt

dz1
= az z0 − d1 z1 ,
dt

dy2
= b y y1 − d 2 y2 ,
dt

dz2
= bz z1 − d2 z2 ,
dt

dy3
= cy y2 − d 3 y3 .
dt

dz3
= cz z2 − d3 z3 .
dt

(1)

Kim et al. modiﬁed the model of Michor et al. to include the antileukemia immune response. In particular, Kim et al. used experimental T-cell data from [3] to measure the immune response during imatinib treatment of CML. To include the dynamics of the anti-leukemia
T-cell response in the mathematical model of CML, Kim et al. added
an additional term to each of the equations of the model of Michor
et al. to account for the interaction between cancer cells and T-cells
that results in death of leukemia cells. In addition, Kim et al. added a
delay-differential equation dT
to describe the evolution of the T-cell
dt
population T during imatinib treatment. The mathematical model of
Kim et al. which includes the immune response and imatinib resistance is given by the following:

dy0
= (ry (1 − u) − d0 )y0 − qC p(C, T )y0 ,
dt
dy1
= ay y0 − d1 y1 − qC p(C, T )y1 ,
dt
dy2
= by y1 − d2 y2 − qC p(C, T )y2 ,
dt
dy3
= cy y2 − d3 y3 − qC p(C, T )y3 .
dt
dz0
= (rz − d0 )z0 + ry uy0 ,
dt

Table 2
Estimates of parameters [6,11].
Parameter

Description

Estimate

λ
d0
d1
d2
d3
ry
ay

Fractional adjustment constant
Stem cell death rate
Progenitor cell death rate
Differentiated cell death rate
Terminal cell death rate
Stem cell regeneration rate
Stem cell growth rate

0.75
0.003 λ/day
0.008 λ
0.05 λ

by

Progenitor cell growth rate

cy
rz
az
bz
cz
k
p0
qC
qT

Differentiated cell growth rate
Imatinib resistant mutation stem cell regeneration rate
Imatinib resistant mutation stem cell growth rate
Imatinib resistant mutation progenitor cell growth rate
Imatinib resistant mutation differentiated cell growth rate
Kinetic (mixing) coeﬃcient
Probability that T-cell engages cancer cell
Probability that cancer cell dies from
Probability that T-cell survives encounter with cancer cell
Duration of one T-cell division
Average number of T-cell divisions
Anti-leukemia T-cell death rate
Anti-leukemia T-cell supply rate
Decay rate of immune responsivity

τ

n
dT
sT
cn

λ

dz1
= az z 0 − d 1 z 1 ,
dt
dz2
= b z z1 − d2 z2 ,
dt
dz3
= cz z 2 − d 3 z 3 ,
dt
dT
= sT − dT T − p(C, T )C + 2n p(Cnτ , Tnτ )qT Cnτ ,
dt

(2)

where

p(C, T ) = p0 e−cn C kT,

C=

3


yi ,

i=0

Cnτ = C (t − nτ ),

Tnτ = T (t − nτ ).

The cancer cell concentrations yk and zk in this model are the same
as those in the model of Michor et al. The new variable C represents
the total concentration of all leukemia cells, and the new variable T
represents the concentration of anti-leukemia T cells. The ﬁnal terms
dy
qC p0 e−cn C kTyi in each dtk equation follow the law of mass action,
where kTyi describes the rate of interaction between anti-leukemia
T-cells and the leukemia cell subpopulation yi , and k is the mixing
coeﬃcient. The coeﬃcient p0 is the probability that a T-cell engages
the cancer cell upon interaction, and qC is the probability that the
cancer cell dies from the T-cell response. Additionally, although the
precise mechanism of down-regulation is unknown, it is known that
leukemia cells suppress the anti-leukemia T-cell immune response.
This model describes this suppression by modeling the probability
that a T-cell engages a cancer cell as exponential decay as a function of
the cancer concentration. Thus, the probability of that a T-cell engages
with and kills a cancer cell is given by p0 e−cn C , where cn is the rate of
exponential decay due to down-regulation.
In the DDE dT
, the parameter sT is the constant supply rate of
dt
T-cells, the parameter dT is the natural death rate of T-cells, and
p(C, T )C is the rate at which T-cells engage leukemia cells and commit
to n rounds of division. The ﬁnal term represents the growth of the Tcell population due to division, where τ is the average duration of one
division, and qT is the probability that a T-cell survives the encounter
with an activated leukemia cell. Finally, Cnτ and Tnτ are the total can-

0.008/day
1.6 (without imatinib treatment)
1.6/100 (with imatinib treatment)
10 (without imatinib treatment)
10/750 (with imatinib treatment)
100
0.023/day
1.6
10
100
1 (k/μL)−1 per day
0.8
0.75
0.5
1 day
Patient-dependent
Patient-dependent
Patient-dependent
Patient-dependent

cer and T-cell concentrations at time t − nτ , respectively. Once a T-cell
begins the division process, it exits the collection of active T-cells and
re-enters the system nτ time units later after n divisions.
The estimated values of the universal parameters for this system
are given in Table 2 (and are taken from [11] and [6]). The parameters
n, sT , dT , and cn are patient-dependent parameters, and in [6] the
authors used experimental data from Chen et al. [3] to estimate these
values for particular patients in the case without imatinib resistance,
i.e. u = 0 and z0 (0) = 0. We will study three patients, labelled P1, P4,
and P12, in detail, as these were the patients in the Chen et al. study
with the most available data.
In this work, we use the cancer and T-cell data from Chen et al.
[3] to derive new values for these patient-dependent parameters in
the presence of imatinib resistance. In particular, we set the initial
concentration z0 (0) to 10−9 (k/μL), which corresponds to an initial
resistant stem cell count of approximately 10 cells, and we set u,
the rate of imatinib-resistant mutations, equal to 4 × 10−8 mutations
per division. We also note, however, that mathematical modeling
and data analysis in [18] suggests that u may be as high as 10−4 ,
and in future work, we plan to incorporate the models of that work
into our modeling work. Using the T-cell data presented in [3] and
known information from the immunological literature [2,5,9] about
reasonable ranges for the parameters, we simulated the DDE model
to obtain new values for the patient-dependent parameters for P1, P4,
and P12 in the presence of imatinib resistance. These new parameter
values are the primary difference between this model and the studies
presented in [6] and [12], as those studies ignored the possibility of
imatinib resistance. Our goal in this work is to evaluate the potential
eﬃcacy of strategic treatment interruptions as an alternative therapy
program for CML treatment in the presence of imatinib resistance.
The values of these newly-derived patient-dependent parameters are
presented in Table 4.
Finally, steady-state conditions are used to obtain the initial conditions, as described in Table 3.
In Fig. 1, we illustrate the graphs of the solutions of the delaydifferential equations mathematical model 2 with the estimated values of the universal and patient-dependent parameters for P1, P4,
and P12, along with the measured data points from [3], in the case
of both initial imatinib resistance and a non-zero resistance mutation rate. These solutions represent continuous imatinib treatment.

Table 3
Initial leukemia and T-cell concentrations [11].
 
Population
Population
Value μkL
y0 (0)
y1 (0)
y2 (0)
y3 (0)
T (0)

Patient-dependent
ay y0 (0)
d1
by y1 (0)
d2
cy y2 (0)
d3
sT
dT

z0 (0)
z1 (0)
z2 (0)
z3 (0)

 
Value μkL
1 × 10−9
az z0 (0)
d1
bz z1 (0)
d2
cz z2 (0)
d3

As illustrated in Fig. 1, and as discussed extensively in [6] and [12] (in
the case without imatinib resistance), continuous imatinib treatment
does not completely eliminate leukemia, and all patients eventually
relapse with continuous imatinib treatment. Additionally, this model
with imatinib resistance predicts an earlier relapse with continuous
imatinib treatment as compared to the model simulations that do not
include resistance in [6] and [12], as expected.
In [6] and [12], the ﬂuctuations that occur in the anti-leukemia
T-cell concentrations corresponding to ﬂuctuations that occur in the
leukemia cell concentrations are discussed in great detail. The key
observations are as follows:
•

•

•

Initially, the T-cell concentrations are low, as the immune response
is nearly fully repressed by leukemia.
As imatinib treatment begins to take effect, the leukemia cell concentrations decrease, and the patient’s immune response is eventually stimulated and the T-cell concentrations increase.
As the patient’s immune response combines with imatinib treatment to combat leukemia, the leukemia cell concentrations decrease, and eventually the T-cells are no longer stimulated and
their concentration begins to decrease.

From these observations, we conclude that there is a critical time
period during which the patient’s immune response is maximally activated, and we seek to devise treatment strategies that optimally
leverage the immune response. In [12], the authors studied a wide
range of strategic treatment interruptions (STIs) in which imatinib
treatment is temporarily stopped in order to stimulate the immune
response. The length and starting time of the treatment interruption
were varied, and the authors measured the maximum leukemia concentration observed after the STI is administered, the minimum total
leukemia concentration observed during treatment, the time required
for the patient to achieve cytogenetic remission, and the time required
for total cancer elimination (if total elimination occurs). However, the
authors did not consider the possibility of imatinib resistance in the
initial study.
3. Results
In this work, we study the eﬃcacy of numerous strategic treatment interruption simulations in which we incorporate acquired
(u = 4 × 10−8 mutations per division) and innate imatinib resistance
(z0 (0) = 1 × 10−9 k/μL). In Fig. 2, we plot the leukemia and T-cell
concentrations for each patient for 0 ≤ t ≤ 50 months, with a 15-day
STI starting at time t = 6 months (t = 180 days). We observe that
interrupting imatinib treatment results in a 5-fold increase in T-cell
concentration as compared to continuous imatinib treatment.
As in [12], we also note that, as a result of the stoppage of imatinib treatment from t = 180 to t = 195 days, there is a fast rise in the
concentration of leukemia cells while imatinib treatment is stopped.
However, this increase does not reach the initial level of leukemia
cells present in the patient prior to beginning imatinib treatment.
For example, for patient P1, the maximum leukemia concentration

Fig. 1. Model solutions of system (2) ﬁt to T-cell data for patients P1 (top), P4 (middle),
and P12 (bottom) in the presence of initial imatinib resistance and non-zero imatinib
resistance mutation rate. The numerical values of the parameters are those in Tables 2
and 4.

attained after imatinib treatment is stopped is 11.00 k/μL; the initial
pre-treatment leukemia concentration for patient P1 is 73.0 k/μL.
For all patients, the increase in leukemia concentration that occurs
following the stoppage of imatinib treatment does not approach the
initial pre-treatment leukemia concentrations. See Table 4 for the pretreatment leukemia concentrations for each patient. Once imatinib
treatment is restarted, the leukemia concentration decreases rapidly,
and for patients P1 and P4, leukemia is completely eliminated as a
result of the STI. We also note that the peaks after treatment is interrupted are higher than the peaks in the non-resistant case discussed
in [12], so studying the effects of imatinib resistance is an important
consideration when evaluating strategic treatment interruptions as a
possible alternative therapy program for CML patients.
In Tables 5–7, we present the results of several 15-day treatment
interruptions for patient P1, P4, and P12 with varying starting times.
For each STI, we report the maximum leukemia concentration observed after the STI is administered, the minimum total leukemia
concentration observed during treatment, the time required for the
patient to achieve cytogenetic remission, and the time required for
total cancer elimination (if total elimination occurs), as in [12].
Although patients P1 and P4 achieve complete leukemia elimination with several 15-day strategic treatment interruptions (as was the
case in [12] without imatinib resistance), we observe that patient P12
never achieves leukemia elimination with any 15-day STI. The minimum leukemia concentrations presented in Tables 5–7 are much
higher than the minimum leukemia concentrations that are achieved
in [12] in which imatinib resistance is ignored. Thus, a patient with
resistant cells will have a lower chance of complete elimination than
a patient with no imatinib-resistant leukemia cells.
The observation that patient P12 does not attain leukemia elimination with any 15-day STI represents a signiﬁcant difference from
the results obtained in [12] without imatinib resistance, as all patients achieved leukemia elimination with a 15-day STI when the
possibility of imatinib resistance was ignored. Thus, the case of patient P12 illustrates the importance of considering the possibility of
innate and/or acquired imatinib resistance. Patient P12 has an initial
leukemia concentration that is an order of magnitude greater than
the initial concentrations of the other two patients; we believe that
this may be an important factor that affects whether or not leukemia
can be eliminated with a single treatment interruption. We also note
(but do not include the numerical results here) that patient P12 also
does not achieve elimination with any 30-day or 45-day STI.
However, two well-timed strategic treatment interruptions do
lead to leukemia elimination for patient P12. As illustrated in Fig. 3,
if we interrupt imatinib treatment at t = 150 days for 30 days and
again at t = 390 days for 60 days, patient P12 will reach a minimum
leukemia concentration of 1.40 × 10−6 k/μL, which is below the elimination criteria. In Fig. 3, we observe two peaks of leukemia cells and
two corresponding T-cell peaks, corresponding to the two separate
treatment interruptions.
These results illustrate that strategic treatment interruptions may
present a viable alternative therapy program for chronic myelogenous
leukemia, even when the patient has an initial count of imatinibresistant leukemia cells and/or a non-zero resistance mutation rate.
However, as indicated by the results for P12, the patient-dependent
parameters play an important role in whether or not leukemia can be
eliminated, and more than one treatment interruption and/or interruptions of various durations may be required to achieve elimination.
In the future, we plan to study this optimization problem in more
detail as a formal optimal control problem.
Fig. 2. Leukemia and T-cell concentrations obtained by simulating the model in system
(2) for P1, P4, and P12 for 0 ≤ t ≤ 1500 days with a 15-day STI from t = 180 to t = 195
days with imatinib resistance.

4. Sensitivity analysis
To study the sensitivity of our results on the numerical values of the parameters and patient-dependent initial conditions in

Table 4
Values of patient-dependent parameters obtained with imatinib-resistant mutations and initial
imatinib-resistant cells: u = 4 × 10−8 mutations per division and z0 (0) = 1 × 10−9 k/μL. These
new values represent a major advancement of this work, as earlier work with this model in [6] and
[12] did not consider the possibility of imatinib resistance.
Patient

n

dT

sT

cn

y0 (0)

Initial total leukemia
concentration (k/μL)

P1
P4
P12

1.195
1.495
1.1685

0.0016
0.0033
0.007

2.28 × 10−6
1.34 × 10−6
3.08 × 10−5

0.85
2.00
0.80

7.6 × 10−6
2.4 × 10−6
1.2 × 10−5

73.0
23.1
116.8

Table 5
Results of several 15-day STI plans for patient P1 with imatinib resistance.
Treatment
plan: ﬁrst
day of
15-day STI

Maximum leukemia
concentration
(k/μL) after STI
is administered

Minimum
leukemia
concentration
(k/μL)

Time until
cytogenetic
remission
(days)

Time until
total cancer
elimination
(days)

No STI
90
120
150
180
210
240
270
300
330
360
390

n/a
20.61 at t = 106
17.22 at t = 136
14.29 at t = 166
11.00 at t = 196
7.91 at t = 227
5.55 at t = 257
3.92 at t = 287
2.83 at t = 317
2.11 at t = 347
1.62 at t = 377
1.28 at t = 407

3.70 × 10−3
1.40 × 10−3
6.67 × 10−6
4.07 × 10−10
1.22 × 10−13
7.06 × 10−16
3.16 × 10−17
2.09 × 10−17
3.24 × 10−16
3.07 × 10−14
3.58 × 10−12
2.30 × 10−10

278
339
310
307
317
331
348
368
278
278
277
277

n/a
n/a
n/a
n/a
730
639
613
624
675
770
933
n/a

Tables 2 and 4 on the effectiveness of the strategic treatment interruption strategies that we considered in Section 3, we apply the
Latin Hypercube sampling (LHS) method described in [10]. The LHS

technique provides a method for simultaneously sampling a wide
range of parameters and statistically determining the correlation between the values of the parameters and various outcomes. We simulate the delay-differential equation model with various strategic
treatment interruptions with randomly sampled sets of parameters;
using LHS, the values of the parameters are chosen in such a way that
each parameter is well-distributed over its range of possible values.
In particular, the parameters are sampled uniformly to include the
ranges of the parameter values for all patients analyzed in [3], as indicated in Table 9. We vary every parameter and initial condition used
in the model. We perform 500 simulations of strategic treatment interruptions for 15 days for each patient. Times at which the STIs start
are t = 90 to t = 390 days in 30-day increments.
In Table 8, we report the fraction of LHS samples that result in a
successful treatment. A success is deﬁned as a simulation in which
the total cancer concentration falls below 10−10 k/μL (i.e. a simulation in which the cancer concentration falls below the elimination
criterion). We observe a bell-shaped pattern for each patient; peak
success rates are for 15-day STIs that start at month 7, 6, and 5 for patients P1, P4, and P12 respectively. This pattern is due to timing of the
peak T-cell expansion rate in conjuction with T-cell stimulation via

Table 6
Results of several 15-day STI plans for patient P4 with imatinib resistance.
Treatment
plan: ﬁrst
day of
15-day STI

Maximum leukemia
concentration
(k/μL) after STI
is administered

Maximum
T-cell
concentration
(k/μL)

Minimum
leukemia
concentration
(k/μL)

Time until
cytogenetic
remission
(days)

Time until
total cancer
elimination
(days)

No STI
90
120
150
180
210
240
270
300
330
360
390

n/a
6.52 at t = 106
5.45 at t = 136
4.55 at t = 166
3.59 at t = 196
2.72 at t = 227
2.02 at t = 257
1.51 at t = 287
1.15 at t = 317
0.89 at t = 347
0.71 at t = 377
0.57 at t = 407

1.75 × 10−2
2.90 × 10−2
6.19 × 10−2
1.09 × 10−1
1.46 × 10−1
1.71 × 10−1
1.86 × 10−1
1.89 × 10−1
1.78 × 10−1
1.59 × 10−1
1.37 × 10−1
1.17 × 10−1

5.60 · 10−3
1.40 · 10−3
1.11 · 10−5
4.52 · 10−9
7.14 · 10−12
7.94 · 10−14
4.55 · 10−15
2.47 · 10−15
1.53 · 10−14
4.39 · 10−13
1.92 · 10−11
6.38 · 10−10

252
301
279
282
295
312
330
252
252
252
252
252

n/a
n/a
n/a
n/a
688
581
557
573
617
702
870
n/a

at t = 354
at t = 344
at t = 294
at t = 292
at t = 304
at t = 320
at t = 338
at t = 360
at t = 384
at t = 411
at t = 440
at t = 470

Table 7
Results of several 15-day STI plans for patient P12 with imatinib resistance.
Treatment
plan: ﬁrst
day of
15-day STI

Maximum leukemia
concentration
(k/μL) after STI
is administered

Maximum
T-cell
concentration
(k/μL)

Minimum
leukemia
concentration
(k/μL)

Time until
cytogenetic
remission
(days)

Time until
total cancer
elimination
(days)

No STI
90
120
150
180
210
240
270
300
330
360
390

n/a
32.53 at t = 106
27.03 at t = 136
21.35 at t = 166
13.84 at t = 196
7.66 at t = 227
4.23 at t = 257
2.54 at t = 287
1.69 at t = 317
1.24 at t = 347
0.987 at t = 377
0.838 at t = 407

3.13 × 10−2
3.29 × 10−2
4.73 × 10−2
7.71 × 10−2
1.05 × 10−1
1.23 × 10−1
1.25 × 10−1
1.04 × 10−1
7.68 × 10−2
5.68 × 10−2
4.35 × 10−2
3.48 × 10−2

2.80 × 10−3
3.80 × 10−3
1.10 × 10−3
7.05 × 10−5
4.27 × 10−6
5.66 × 10−7
2.88 × 10−7
1.53 × 10−6
1.49 × 10−5
8.48 × 10−5
2.70 × 10−4
5.79 × 10−4

246
320
319
316
320
327
339
246
246
246
246
246

n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a

at t = 210
at t = 281
at t = 295
at t = 303
at t = 311
at t = 320
at t = 333
at t = 354
at t = 381
at t = 410
at t = 449
at t = 469

Fig. 3. Leukemia and T-cell concentrations for P12 for 0 ≤ t ≤ 1050 days with two STIs, one from t = 150 to t = 180 days and a second from t = 390 to t = 450 days.

Table 8
Fraction of LHS samples that result in a successful treatment. A success is deﬁned
as a simulation in which the total cancer population falls below 10−10 k/μL.
Treatment
plan:
start of 15-day STI

Fraction of
successful
treatments: P1

Fraction of
successful
treatments: P4

Fraction of
successful
treatments: P12

90
120
150
180
210
240
270
300
330
360
390

0.386
0.440
0.474
0.512
0.520
0.502
0.462
0.446
0.408
0.382
0.368

0.320
0.396
0.460
0.492
0.474
0.434
0.400
0.368
0.274
0.274
0.264

0.296
0.346
0.360
0.340
0.308
0.296
0.278
0.274
0.256
0.260
0.256

Table 9
Sensitivity analysis of parameters performed for patient P1 for a 15-day
strategic treatment interruption from t = 210 to t = 225. For each parameter, we report the estimate of the parameter, the range used for Latin
Hypercube sampling, and the Pearson product-moment correlation (PPMC)
coeﬃcient between the parameter and the minimum cancer concentration.
To obtain the correlation coeﬃcients, we performed 1000 simulations in
which every parameter was varied over the given range.
Parameter

Estimate

Range

PPMC

λ

0.75
0.003λ/day
0.008λ
0.05λ

0.5 to 1
±25%
±25%
±25%
±25%
±25%
±25%

−0.3577
−0.2768
−0.3265
−0.3725
−0.3190
0.0486
0.0385

d0
d1
d2
d3
ry
ay
by

an STI, and in future work we will investigate this relationship more
formally.
We also provide in Table 9 the Pearson product-moment correlation (PPMC) coeﬃcient between each parameter and the minimum
cancer concentration for patient P1 attained during the course of
treatment with a 15-day STI. To obtain the correlation coeﬃcients in
Table 9, we performed 1000 LHS simulations with a strategic treatment interruption from t = 210 to t = 225 days after the start of treatment, and we note that the correlation coeﬃcients obtained with all
other single-interruption STI strategies considered in Section 3 are
comparable.
We observe that n and qT are negatively correlated with the minimum leukemia concentration. This negative correlation occurs because the T-cell population expands primarily through interaction
with cancer cells, as described by the term 2n p(Cnτ , Tnτ )qT Cnτ in the
DDE model. We also observe that the birth rate rz of imatinib-resistant
leukemia cells is correlated with the minimum leukemia concentration by an order of magnitude greater than any other birth rate. This
suggests that imatinib-resistant cells play a key role in the effectiveness of an STI.

cy
rz
az
bz
cz
u
k
p0
qC
qT

τ

n
dT
sT
cn
y0 (0)
T (0)
z0 (0)

λ

0.008
1.6 without imatinib
1.6/100 with imatinib
10 without imatinib
10/750 with imatinib
100
0.01
1.6
10
100
4 · 10−8
1 (k/μL)−1 /day
0.8
0.75
0.5
1 day
1.195
0.0019/day
2.28 · 10−6 k/μL /day
0.85
7.6 · 10−6
0.0012
1 · 10−9

±25%
±25%
±25%
Same as ay
Same as by
Same as cy
4 · 10−8 to 8 · 10−8
±25%
±25%
±25%
±25%
12–24 hours
±25%
±25%
±25%
±25%
±25%
±25%
±25%

0.0658
−0.0062
0.1233
0.0385
0.0658
−0.0062
−0.0076
−0.0544
−0.0011
−0.0019
−0.3187
−0.0163
−0.2420
−0.0087
0.0379
−0.0050
0.0628
−0.0419
0.0225

5. Conclusions
In this paper, we have presented the results of numerous strategic treatment interruption simulations for CML patients with acquired or developed imatinib resistance. Our results demonstrate that

CML can be eradicated even with pre-existing imatinib-resistant cells
and a non-zero imatinib-resistance mutation rate. As expected, we
achieved lower leukemia elimination success rates as compared to
the case without imatinib resistance studied in [12]. In two of the
three patients that we studied in this work, one well-timed STI can be
enough to completely eliminate leukemia; in one patient, two welltimed STIs were required. This work demonstrates that imatinib resistance is an important consideration when studying STIs as a possible
tool for improving treatment of CML, as the results that we obtained
here varied signiﬁcantly from those obtained without resistance in
[12]. The important question remains when to start and end the STI,
and how many STIs are required to successfully cure CML with imatinib. It is clear from the sensitivity analysis conducted in Section 4
that the effectiveness of any STI treatment strategy relies on the numerical values of the parameters and initial leukemia concentration
levels, including resistant cells and resistance mutation rates. Thus, in
a given course of treatment, it is important to estimate the values of
these parameters as early and as accurately as possible to implement
an STI to optimally leverage the patient’s anti-immune response. We
should also note that although we do conduct a sensitivity analysis on
the parameters used in the model (both the patient-dependent and
universal parameters), the primary results in this paper are limited in
scope in that our results are based on data from only three patients.
Still, this work provides a framework for studying strategic treatment
interruptions as a possible therapeutic option for individual patients,
and this work demonstrates that such treatment programs have the
potential to eliminate leukemia, even in the presence of imatinib resistance.
In future work, we plan to study the optimization problems of how
many STIs should occur and when they should begin and end in more
detail. In particular, we wish to analytically determine the optimal
STI strategy for a given patient based on the speciﬁc values of the
patient’s numerical parameters. We also plan to study the stability
of this DDE model in the presence of imatinib resistance. Finally, in
this work, we studied the dynamics of the immune response when
CML is treated with a single drug; in the future, we plan to study
the immune response and possible alternative treatment strategies
when additional drugs (such as dastainib or nilotinib) are used in
conjunction with imatinib.
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